Group 1 - The core viewpoint of the news is that the Hong Kong Stock Connect innovative drug sector is experiencing a significant rally, with leading stocks showing strong gains, indicating a positive market sentiment towards innovative pharmaceuticals [1][3]. - The China National Medical Products Administration reported that 76 innovative drugs were approved for market in 2025, surpassing the total of 48 in 2024, marking a historical high [3]. - The total value of authorized transactions for innovative drugs in China exceeded $130 billion in 2025, with over 150 transactions, also setting a new record [3]. Group 2 - The Hong Kong Stock Connect innovative drug ETF (520880) saw a notable increase, with a peak rise of over 4% and a trading volume of 258 million yuan, surpassing the previous trading day's total [1]. - The ETF tracks the Hang Seng Hong Kong Stock Connect Innovative Drug Select Index, which has three unique advantages: it is purely focused on innovative drug companies, has a high concentration of leading firms, and offers better risk control by reducing the weight of less liquid stocks [3][4]. - The top ten holdings in the ETF account for over 72% of the index's weight, highlighting the dominance of leading innovative drug companies [4].
ETF盘中资讯 久违爆发！港股通创新药ETF（520880）急速飙升4%！国家药监局：2025年我国创新药对外授权超1300亿美元
Jin Rong Jie·2026-01-05 02:49